Iovance Biotherapeutics, Inc. Files Form 8-K With SEC – Company Details, Address, and Stock Information

Posted on March 21, 2026 at 1:15 pm (GMT+8)

NIL
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Please consult with your financial advisor before making any investment decisions.

View IOVANCE BIOTHERAPEUTICS, INC. Historical chart here

TEGNA Inc. Completes Merger with Nexstar Media Group – SEC Form 8-K Filing Details

Ernexa Therapeutics Inc. Files Form 8-K: Notice of Nasdaq Delisting and Company Response – March 2026

Iovance Biotherapeutics, Inc. Files Form 8-K With SEC – Company Details, Address, and Stock Information

View IOVANCE BIOTHERAPEUTICS, INC. Historical chart here

Related Posts

Pliant Therapeutics, Inc. Files Form 8-K on Stockholder Rights Agreement Amendment – Company Details, Address, and Securities Information

Parke Bancorp, Inc. 2025 Annual Report: Financial Performance, Risk Management, and Corporate Overview

Semnur Pharmaceuticals, Inc. 2024 Annual Report: Non-Opioid Pain Management Innovations & SP-102 Clinical Results